Industry News: FDA Clears DyAnsys Neurostimulation Device First Relief to treat Diabetic Neuropathic Pain
First Relief, a PENS (percutaneous electrical neurostimulation) device, has been cleared by the FDA for multiple treatments up to 56 days for symptomatic relief of chronic, intractable pain from diabetic peripheral neuropathy. It is applied behind the ear and delivers continuous pulses of a low-level electrical current over several days.